Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 88.05% is in line with its 5-year average of 92.33%, around the middle of its 5-year range (78.38%–94.22%).
1.02% above its 12-month average of 87.16%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 89.52%.
GROSS MARGIN
88.05%
GROSS MARGIN AVG TTM
87.16%
GROSS MARGIN AVG 3Y
91.65%
GROSS MARGIN AVG 5Y
92.33%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.02%
CURRENT VS 3Y AVG
-3.92%
CURRENT VS 5Y AVG
-4.63%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+112.78%
vs the sector median at left
GoodRx Holdings, Inc.
Market Cap
$1.14B
Gross Margin
88.05%
TTM Avg
87.16%
3Y Avg
91.65%
5Y Avg
92.33%
Market Cap
$1.14B
Gross Margin
47.68%
TTM Avg
50.27%
3Y Avg
51.23%
5Y Avg
48.58%
Market Cap
$1.13B
Gross Margin
73.28%
TTM Avg
75.19%
3Y Avg
72.82%
5Y Avg
72.76%
Market Cap
$1.15B
Gross Margin
99.36%
TTM Avg
84.41%
3Y Avg
76.16%
5Y Avg
77.91%
Market Cap
$1.13B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.11B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.11B
Gross Margin
56.01%
TTM Avg
52.19%
3Y Avg
51.27%
5Y Avg
51.81%
Market Cap
$1.10B
Gross Margin
76.23%
TTM Avg
76.19%
3Y Avg
76.96%
5Y Avg
77.39%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GoodRx Holdings, Inc. (GDRX) | $1.14B | 88.05% | 87.16% | 91.65% | 92.33% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 47.68% | 50.27% | 51.23% | 48.58% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 73.28% | 75.19% | 72.82% | 72.76% |
| Nektar Therapeutics (NKTR)vs › | $1.15B | 99.36% | 84.41% | 76.16% | 77.91% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | 0.00% | 0.00% | 0.00% | 0.00% |
| Replimune Group, Inc. (REPL)vs › | $1.11B | 0.00% | 0.00% | 0.00% | 0.00% |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.11B | 0.00% | 0.00% | 0.00% | 0.00% |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | 56.01% | 52.19% | 51.27% | 51.81% |
| STAAR Surgical Company (STAA)vs › | $1.10B | 76.23% | 76.19% | 76.96% | 77.39% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.18B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
88.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 89.52% |
| 2026-03-31 | 78.38% |
| 2025-12-31 | 91.03% |
| 2025-09-30 | 93.15% |
| 2025-06-30 | 83.71% |
| 2025-03-31 | 93.42% |
| 2024-12-31 | 93.86% |
| 2024-09-30 | 94.02% |
| 2024-06-30 | 94.08% |
| 2024-03-31 | 93.70% |
| 2023-12-31 | 92.29% |
| 2023-09-30 | 89.60% |
| 2023-06-30 | 91.39% |
| 2023-03-31 | 90.93% |
| 2022-12-31 | 90.57% |
| 2022-09-30 | 90.71% |
| 2022-06-30 | 90.59% |
| 2022-03-31 | 93.96% |
| 2021-12-31 | 93.47% |
| 2021-09-30 | 94.22% |
| 2021-06-30 | 93.72% |
| 2021-03-31 | 93.50% |
| 2020-12-31 | 94.01% |
| 2020-09-30 | 94.63% |
| 2020-06-30 | 94.47% |
| 2020-03-31 | 95.49% |
| 2019-12-31 | 95.94% |
| 2019-09-30 | 96.66% |
| 2019-06-30 | 96.57% |
| 2019-03-31 | 96.52% |
